摘要
目的系统评价厄贝沙坦治疗高血压合并高尿酸血症的疗效和安全性。方法计算机检索Cochrane图书馆(2010年第2期)、MEDLINE、SCI、CBM、CNKI(均从建库至2010年04月),查找采用厄贝沙坦治疗高血压合并高尿酸血症的随机对照试验。按纳入与排除标准选择试验、提取资料和评价其方法学质量后,采用RevMan5.0软件进行Meta分析。结果共纳入9个RCT,977例患者。Meta分析结果显示:厄贝沙坦降低高血压合并高尿酸血症患者血尿酸的疗效要优于对照组[MD=57.12,95%CI(16.08,98.15),P=0.006],其降低血压方面的疗效与对照组相似[收缩压:MD=–0.24,95%CI(–2.19,1.71),P=0.81;舒张压:MD=0.46,95%CI(–1.58,2.50),P=0.66]。厄贝沙坦组不良反应发生率低于对照组[RR=0.07,95%CI(0.02,0.24),P=0.000 1]。结论厄贝沙坦可用于控制高血压合并高尿酸血症患者的血压并降低其血尿酸水平。因9个纳入研究的质量均为C级,故上述结论还需长期、大样本、高质量的研究进一步验证。
Objective To assess the effectiveness and safety of irbesartan for hypertensive patients with hyperuricaemia.Methods The databases such as The Cochrane Library（Issue 2,2010）,MEDLINE（by the end of April 2010）,SCI（by the end of April 2010）,CBM（by the end of April 2010） and CNKI（by the end of April 2010） were searched to collected randomized controlled trails（RCTs） on irbesartan for hypertensive combined with hyperuricaemia.Studies were screened according to the inclusion and exclusion criteria;data were extracted;the methodological quality was evaluated;and meta-analyses were conducted by using RevMan 5.0.0 software.Results Nine studies involving 977 patients were included.The results of meta-analyses showed that compared with the control group,irbesartan was superior in decreasing serum uric acid（SUA）（MD=57.12,95%CI 16.08 to 98.15,P=0.006）;it was similar in controlling blood pressure（Systolic pressure： MD= -0.24,95%CI -2.19 to 1.71,P=0.81;Diastolic pressure： MD=0.46,95%CI -1.58 to 2.50,P=0.66）,and lower in the incidence rate of adverse reaction（RR=0.07,95%CI 0.02 to 0.24,P=0.000？1）.Conclusion The study suggests that irbesartan is effective and safe to control blood pressure and decrease serum uric acid for hypertensive patients with hyperuricaemia.But because all nine included studies are graded C in quality,the conclusion still needs to be further verified by long-term,large scale and high quality studies.
出处
《中国循证医学杂志》
CSCD
2011年第11期1290-1294,共5页
Chinese Journal of Evidence-based Medicine
